MyShare
Overview - ASND US
Ascendis Pharma AS
ASND.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare
Intraday chart for ASND
Please reload the page if latest figures not showing
| United Kingdom's MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism Seite 1 - wallstreet-online de 2h ago - ASND - story | |
| Ascendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic Hypoparathyroidism - rttnews 3h ago - ASND - story | |
| United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism - businessinsider 3h ago - ASND - story | |
| Ascendis Pharma (ASND) Announces UK Approval of YORVIPATH - streetinsider 4h ago - ASND - story | |
| Business brief | Ascendis gets delisting nod, and bubble-tea IPO fizzles in Hong Kong - news24 18:00 Tue - ASND - story |
headline news | recent news | latest news | market news
Chart ASND
Myshare aims to provide good clear honest and easy analysis of financial markets using a scientific, teaching and informative approach. We try hard but please read our disclaimer. Pages are provided by ourselves and our users. Register to edit pages and see the documentation
Global news | headline news | recent news | latest news | market news | topics | stock topics
News topics and stories from around the world and in the selected country
US News | headline news | recent news | latest news | market news | recent topics | stock topics
News from major news outlets like BBC, CNN and Reuters
Forecasts | Forecast buy | Forecast sell | Forecast up | Forecast down | Forecast sector
Long term stock predictions using AI reading the financial accounts of each company.
Ai Predictions | Buys | All up | sell | all down | forecast | History
``` ``` ``` ```